Edge Therapeutics, Inc.
After successfully completing a twenty million dollar round of financing Edge Therapeutics is back to share their path to success with us.
Tuesday, May 28, 2013
The Park Avenue Club, Florham Park, New Jersey (directions)
|
About
|
Edge Therapeutics Inc. is a private, hospital-focused, specialty pharmaceutical company focusing on transforming proven, off-patent drugs into targeted, locally delivered therapies that address unmet medical needs in the acute care setting. Delayed complications are a leading cause of death and permanent brain damage after brain hemorrhage and occur days after the primary injury. This delayed effect provides a "window of opportunity" for doctors to provide protective medications to potentially limit or prevent the delayed complications. Current treatments for delayed complications are expensive, time-consuming and only marginally effective in part because standard delivery methods do not provide adequate and sustained doses of protective drugs at the injury site in the brain. Higher doses that may be more effective cause side effects outside the brain and are unsafe. For many acute CNS conditions, a new method of delivery is greatly desired.
Edge has 5 pre-clinical CNS products with multiple hospital applications that treat secondary complications following bleeding in the brain (brain hemorrhage). Edge's products will be developed via a well-defined and abbreviated 505(b)(2) path. Further, the targeted indications address rare conditions and meet the criteria for orphan designation. Edge’s lead product NimoGelTM, is being developed in collaboration with SurModics, Inc., a leading provider of drug delivery technologies to the healthcare industry (Nasdaq: SRMX), to prevent a complication called delayed cerebral ischemia (DCI). Edge has recently completed a proof-of-principle large animal study, held its pre-IND meeting with FDA and has entered clinical studies.
Edge Therapeutics was PCCI of New Jersey’s first presenter. Now two years later Brian Leuthner is back to share with us just how they achieved that success, what worked for them and those things that were not so successful.
Major Issues
|
Open discussion
Program:
|
6:30 - Cocktails & Dinner (special 2-entree buffet menu)
8:00 – Brian A. Leuthner, President and CEO of Edge Therapeutics, Inc., will deliver the Company’s "Elevator" pitch to the group,
8:45 -Open discussion: members and guests
<Top of the page>
|
 |
Reserve your dinner for this month's meeting online now though PayPal.
Please note: You do not need a PayPal account to reserve your spot, most credit cards are accepted.
|
|
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
